Welcome to our dedicated page for Nurexone Biologic news (Ticker: NRXBF), a resource for investors and traders seeking the latest updates and insights on Nurexone Biologic stock.
NurExone Biologic Inc. (NRXBF) news focuses on its progress as a preclinical biotechnology company developing regenerative exosome-based therapies for central nervous system injuries. The company’s updates highlight advances in its lead candidate ExoPTEN, exosome manufacturing capabilities, regulatory milestones, intellectual property, and financing activities that support its development plans.
Readers following NurExone’s news can see detailed reports on preclinical data, including dose-dependent recovery of visual function in glaucoma and optic nerve injury models and motor recovery in acute spinal cord injury models. The company also publishes laboratory analyses showing anti-inflammatory activity of its exosomes and higher biological activity compared with commercially available exosome products, which it presents as strengthening the rationale for its platform.
News releases also cover regulatory and scientific visibility, such as Orphan Drug Designation for ExoPTEN in acute spinal cord injury and invited presentations at international conferences on exosomes, regenerative medicine, and bioprocessing. These items provide insight into how NurExone is engaging with regulators and the scientific community around exosome-based therapeutics.
On the corporate side, NurExone reports on patent developments, including a U.S. Notice of Allowance and an Israeli patent grant for its exosome manufacturing process, as well as its participation in programs like ARMI’s BioFab Startup Lab. Investors can also track capital raises, warrant exercises, and private placements that fund R&D, manufacturing initiatives, and U.S. expansion through its subsidiary Exo-Top Inc., including plans for a commercial exosome production facility in Indianapolis, Indiana.
For anyone monitoring NRXBF, this news stream offers a consolidated view of scientific results, manufacturing readiness, regulatory positioning, and financial developments that shape NurExone’s trajectory in exosome-based CNS therapies.
NurExone (OTCQB: NRXBF) announced three developments on March 11, 2026: a consulting agreement with Dr. Lars Bärfacker to support European scientific initiatives, finalist status in the Healthcare category of the 2026 BOLD Awards in Barcelona, and the closing of a non‑brokered private placement of 1,295,222 units at C$0.68 per unit for gross proceeds of approximately $880,750.96, subject to TSXV approval.
Each unit includes one common share and one warrant exercisable at C$0.85 for 36 months, with a potential acceleration provision if the 20‑day VWAP reaches C$1.70. Proceeds are for general working capital.
NurExone (OTCQB: NRXBF) will present at two international conferences in March 2026: NANO.IL.2026 (Jerusalem, March 8–10) and the Advanced Therapies Congress (London). CEO Dr. Lior Shaltiel is an invited speaker and co-chair at NANO.IL.2026 and will speak in London.
The Company said its exosome platform targets minimally invasive regenerative therapies for central nervous system injuries. Corporate update: Jacob Licht will step down from his roles at the end of March 2026 and management will assume his responsibilities until further notice.
NurExone Biologic (OTCQB: NRXBF) reported independent proteomic analysis from Technion showing consistent protein fingerprints across four exosome production batches, supporting CMC readiness and informing a potential Investigational New Drug (IND) filing.
The analysis found several proteins present in NurExone exosomes but absent in a commercial reference, and the company noted near-term plans for small-scale clinical manufacturing in Israel and potential U.S. steps via Exo-Top, subject to financing.
NurExone (OTCQB: NRXBF / TSXV: NRX) appointed Eyal Gabbai to its board effective Jan 30, 2026, replacing Dr. Gadi Riesenfeld, who will join the Scientific Advisory Board. The company said Gabbai’s healthcare leadership and capital markets experience will support movement of preclinical exosome programs toward first-in-human milestones and potential future capital markets opportunities.
Gabbai chairs Meuhedet, serving ~1.4 million members with annual turnover exceeding US$3 billion, and previously led government privatizations totaling over US$5 billion.
NurExone (OTCQB: NRXBF) announced laboratory data (Dec 19, 2025) showing its bone marrow–derived MSC exosomes markedly reduce inflammatory signaling versus untreated inflamed cells and a commercially available exosome control.
Key findings: NurExone exosomes lowered IL-6 by >86% at all concentrations tested and reduced TNF-α by >62% at the highest concentration, with a clear concentration-dependent effect. The company says results support its ExoPTEN approach and platform development for consistent, scalable exosome therapeutics.
NurExone (OTCQB: NRXBF) announced on December 12, 2025 that it has begun evaluating Israeli partners for small-scale GMP-aligned manufacturing of its lead candidate ExoPTEN to support preparation for a potential First-in-Human use pathway, pending regulatory approval.
NurExone reported new analytical data showing its MSC-derived exosomes convert AMP to adenosine at a significantly higher per-particle rate versus a commercial control (t-test, p < 0.01). The company engaged Russo Partners for a short consulting project for US$6,600.
NurExone Biologic (OTCQB: NRXBF, TSXV: NRX) reported Q3 2025 results and a corporate update on Nov 28, 2025. Key highlights include C$3.2 million gross proceeds from accelerated warrant exercises, C$1.4 million raised in August/September 2025 private placements, and strengthened IP with a U.S. notice of allowance (Sept 8, 2025) and an Israel patent grant (Nov 11, 2025). Preclinical programs showed reproducible, dose-dependent vision recovery in glaucoma models and dose-dependent motor recovery in acute spinal cord injury. The company secured an incentive offer up to US$0.26 million for a planned Indianapolis GMP facility, granted 1,450,000 RSUs and 271,700 options, and reported a Q3 net loss of US$1.47 million.
NurExone (OTCQB: NRXBF) announced it received C$3,185,994.43 in gross proceeds from accelerated warrant exercises completed after acceleration notices issued on October 8, 2025.
The company reported C$1,207,418.88 from 2,515,456 September 2023 warrants at C$0.48 each and C$1,978,575.55 from 5,653,073 January 2024 warrants at C$0.35 each. Proceeds will be used for general corporate purposes and working capital to support development of its exosome-based therapeutic platform, including ExoPTEN. NurExone also received finalist recognition at Falling Walls (Berlin) and Prix Galien Bridges (Stockholm, December 5, 2025).
NurExone (OTCQB: NRXBF) was accepted into the ARMI BioFab Startup Lab under the federally supported BioFabUSA program on Nov 3, 2025. The program aims to accelerate translation of regenerative innovations into scalable, commercially viable manufacturing.
The company said participation could support plans by its U.S. subsidiary Exo-Top to develop a GMP-compliant facility for naive exosome production and may enhance its value proposition to strategic partners and shareholders.
NurExone (OTCQB: NRXBF) announced that Dr. Ina Sarel, Director of Clinical and Regulatory Affairs, will present at the Precision EV Forum 2025 in Cambridge, UK on October 27–28, 2025. Dr. Sarel will speak on October 28 about regulatory challenges in the clinical development of ExoPTEN: MSC EVs loaded with PTEN-siRNA and will join a panel on regulatory pathways for exosome therapeutics.
The invitation highlights international interest in NurExone’s lead program ExoPTEN, which has Orphan Drug Designation for acute spinal cord injury and has shown nerve-function restoration and reduced inflammation in preclinical models for spinal cord and optic nerve damage.